Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda

AIDS Patient Care and STDs

Volumn 22, Issue 10, 2008, Pages 787-795

  Weidle, Paul J ^a,c   Moore, David ^b   Mermin, Jonathan ^b,d   Buchacz, Kate ^a,c   Were, Willy ^b   Downing, Robert ^b   Kigozi, Aminah ^b   Ndazima, Vincent ^b   Peters, Philip ^a,c   Brooks, John T ^a,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COTRIMOXAZOLE; EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; ISONIAZID; LIVER ENZYME; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; DOSE LIVER FUNCTION RELATION; ENZYME ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RASH; RURAL AREA; TUBERCULOSIS; UGANDA;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; LIVER; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; REVERSE TRANSCRIPTASE INHIBITORS; RISK; TRANSAMINASES; UGANDA;

EID: 53849083073     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0020     Document Type: Article

References (35)

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: Towards universal access. Recommendations for a public health approach: 2006 revision. www.who.int/ (Last October 10, 2006).
2. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887-895.
3. Pujari SN, Patel AK, Naik E, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr 2004;37:1566-1569.
4. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005;353:2325-2334.
5. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes. JAMA 2006;296:782-793.
6. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: Experience from western Kenya. AIDS 2006;20:41-48.
7. Viramune. Boehringer Ingelheim Pharmaceuticals, Inc 2005.
8. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://AIDSinfo.nih.gov (Last October 10, 2006).
9. Weidle PJ, Wamai N, Solberg P, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006;368:1587-1594.
10. Buchacz K, Weidle PJ, Moore D, et al. Changes in lipid profile over 24 months among adults on first-line HAART in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007;47:304-311.
11. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. www3.niaid.nih.gov (Last accessed 1, 2004).
12. Forna F, Liechty CA, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007;44:456-462.
13. Drugs for tuberculosis. Treat Guidel Med Lett 2007;5:15-22.
14. Ramachandran G, Hemanthkumar AK, Rajasekaran S, et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr 2006;42:36-41.
15. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: A prospective, open-label observational study. J Acquir Immune Defic Syndr 2004;35:492-502.
16. Manfredi R, Calza L, Chiodo F. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine. HIV Clin Trials 2005;6:302-311.
17. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005;191:825-829.
18. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003;34(Suppl 1):S21-S33.
19. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002;35:182-189.
20. van LF, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-1263.
21. Kim AA, Wanjiku L, Macharia DK, et al. Adverse Events in HIV-Infected Persons Receiving Antiretroviral Drug Regimens in a Large Urban Slum in Nairobi, Kenya, 2003-2005. J Int Assoc Physicians AIDS Care (Chic Ill ) 2007;6:206-209.
22. Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr 2006;43:320-323.
23. Bonjoch A, Paredes R, Domingo P, et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2006;22:321-329.
24. Zhou J, Phanupak P, Kiertiburanakul S, Ditangco R, Kamarulzaman A, Pujary S. Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database. J Acquir Immune Defic Syndr 2006;43:501-503.
25. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. AIDS 1997;11:597-606.
26. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: Promises and pitfalls. Clin Infect Dis 2006;43:904-910.
27. Nunez M, Ramos B, az-Pollan B, et al. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses 2006;22:842-848.
28. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007;356:1445-1454.
29. Echevarria JM, Avellon A. Hepatitis B virus genetic diversity. J Med Virol 2006;78(Suppl 1):S36-S42.
30. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007;7:402-409.
31. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007;21:713-719.
32. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007;12:929-935.
33. Moore D, Yiannoutsos CT, Musick B, et al. Determinants of mortality among HIV-infected individuals receiving home-based ART in rural Uganda. 14th Conference on Retroviruses and Opportunistic Infections. February 25, 2007.
34. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-1268.
35. Hladik W, Kataaha P, Mermin J, et al. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors. Trop Med Int Health 2006;11:951-954.